1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32214
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCarneiro, Benedito A-
dc.contributor.authorPapadopoulos, Kyriakos P-
dc.contributor.authorStrickler, John H-
dc.contributor.authorLassman, Andrew B-
dc.contributor.authorWaqar, Saiama N-
dc.contributor.authorChae, Young Kwang-
dc.contributor.authorPatel, Jyoti D-
dc.contributor.authorShacham-Shmueli, Einat-
dc.contributor.authorKelly, Karen-
dc.contributor.authorKhasraw, Mustafa-
dc.contributor.authorBestvina, Christine M-
dc.contributor.authorMerrell, Ryan-
dc.contributor.authorHuang, Kevin-
dc.contributor.authorAtluri, Harisha-
dc.contributor.authorAnsell, Peter-
dc.contributor.authorLi, Rachel-
dc.contributor.authorJin, Janet-
dc.contributor.authorAnderson, Mark G-
dc.contributor.authorReilly, Edward B-
dc.contributor.authorMorrison-Thiele, Gladys-
dc.contributor.authorPatel, Kalpesh-
dc.contributor.authorRobinson, Randy R-
dc.contributor.authorAristide, Martha R Neagu-
dc.contributor.authorGan, Hui K-
dc.date2022-
dc.date.accessioned2023-03-01T03:55:58Z-
dc.date.available2023-03-01T03:55:58Z-
dc.date.issued2023-
dc.identifier.citationNeuro-oncology advances 2023; 5(1):vdac183en_US
dc.identifier.issn2632-2498-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32214-
dc.description.abstractSerclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer. We investigated Ser-T monotherapy in a phase I, first-in-human, dose-escalation, and dose-expansion study in patients with advanced solid tumors associated with EGFR overexpression.en_US
dc.language.isoeng-
dc.subjectEGFRen_US
dc.subjectantibody-drug conjugateen_US
dc.subjectglioblastomaen_US
dc.subjectphase Ien_US
dc.subjectserclutamab talirineen_US
dc.titlePhase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleNeuro-oncology advancesen_US
dc.identifier.affiliationLegorreta Cancer Center at Brown University, Providence, Rhode Island, USA.en_US
dc.identifier.affiliationSTART San Antonio, San Antonio, Texas, USA.en_US
dc.identifier.affiliationDivision of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA.en_US
dc.identifier.affiliationDivision of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, the Herbert Irving Comprehensive Cancer Center, New York, New York, USA.en_US
dc.identifier.affiliationDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.en_US
dc.identifier.affiliationFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.en_US
dc.identifier.affiliationRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.en_US
dc.identifier.affiliationDepartment of Oncology, Sheba Medical Center, Ramat Gan, Israel.en_US
dc.identifier.affiliationUniversity of California Davis Comprehensive Cancer Center, Sacramento, California, USA.en_US
dc.identifier.affiliationThe Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA.en_US
dc.identifier.affiliationThe University of Chicago Medicine, Chicago, Illinois, USA.en_US
dc.identifier.affiliationDepartment of Neurology, NorthShore University Health System, Evanston, Illinois, USA.en_US
dc.identifier.affiliationAbbVie Inc., North Chicago, Illinois, USA.en_US
dc.identifier.affiliationAbbVie Inc., South San Francisco, California, USA.en_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.doi10.1093/noajnl/vdac183en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-5468-1126en_US
dc.identifier.orcid0000-0001-7386-9928en_US
dc.identifier.orcid0000-0003-3249-9849en_US
dc.identifier.pubmedid36814898-
dc.description.volume5-
dc.description.issue1-
dc.description.startpagevdac183-
local.name.researcherGan, Hui K
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

88
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.